



December 26, 2006

## **U.S. Appeals Court Upholds Lilly's 2011 Zyprexa Patent**

INDIANAPOLIS, Dec 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- The Court of Appeals for the Federal Circuit in Washington, D.C., today affirmed the U.S. District Court's decision that upheld Eli Lilly and Company's (NYSE: LLY) Zyprexa(R) patent expiring in 2011. Oral arguments were heard on April 6, 2006, by the appeals court. On April 14, 2005, in the case of Eli Lilly and Company v. Zenith Goldline Pharmaceuticals et al., the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly on all of the generic companies' patent challenges, including obviousness, double patenting, inequitable conduct, anticipation, and public use.

"Today's appeals court ruling not only affirms the validity of our patent, but upholds patent law that helps enable the significant investments required to develop the next generation of revolutionary medicines for the patients who need them," said Sidney Taurel, Lilly chairman and chief executive officer.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at [www.lilly.com](http://www.lilly.com). C-LLY

Zyprexa(R)(olanzapine, Lilly)

SOURCE Eli Lilly and Company

Phil Belt of Eli Lilly and Company, +1-317-748-3915

<http://www.lilly.com>

Copyright (C) 2006 PR Newswire. All rights reserved

News Provided by COMTEX